SRPT
Sarepta Therapeutics Inc
NASDAQ: SRPT · HEALTHCARE · BIOTECHNOLOGY
$19.40
-5.46% today
Updated 2026-06-05
Market cap
$1.89B
P/E ratio
51.06
P/S ratio
0.83x
EPS (TTM)
$0.35
Dividend yield
—
52W range
$10 – $44
Volume
3.0M
WallStSmart proprietary scores
59
out of 100
Grade: C+
Hold
Investment rating
7.3
Growth
B+6.0
Quality
B5.5
Profitability
C+3.0
Valuation
D4/9
Piotroski F-Score
Moderate
-1.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$22.00
+13.40%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy8 Buy12 Hold3 Sell2 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Altman Z -1.24 — distress zone
- Thin margins at 2.98%
- Negative free cash flow $-204.76M
- Revenue declining -1.90% QoQ
- P/E 51.06x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $933.01M | $1.24B | $1.90B | $2.20B | $2.18B |
| Net income | $-703.49M | $-535.98M | $235.24M | $-713.41M | $330.96M |
| EPS | — | — | — | — | $0.35 |
| Free cash flow | $-357.60M | $-588.34M | $-352.74M | $-307.45M | $-204.76M |
| Profit margin | -75.40% | -43.11% | 12.37% | -32.45% | 2.98% |
Peer comparison
Smart narrative
Sarepta Therapeutics Inc trades at $19.40. representing a P/E of 51.06x trailing earnings. Our Smart Value Score of 59/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -1.24, it sits in the distress. TTM revenue stands at $2.18B. with profit margins at 2.98%.
Frequently asked questions
What is Sarepta Therapeutics Inc's stock price?
Sarepta Therapeutics Inc (SRPT) trades at $19.40, on a P/E of 51.1x and a P/S of 0.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Sarepta Therapeutics Inc overvalued?
Sarepta Therapeutics Inc carries a Smart Value Score of 59/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Sarepta Therapeutics Inc (SRPT)?
The 12-month analyst consensus target is $22.00, about 13.4% above the current $19.40. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Sarepta Therapeutics Inc's revenue?
Sarepta Therapeutics Inc's trailing twelve-month revenue is $2.18B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Sarepta Therapeutics Inc's Altman Z-Score is -1.24, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio0.83x
ROE4.32%
Beta0.26
50D MA$20.08
200D MA$19.96
Shares out0.11B
Float0.09B
Short ratio—
Avg volume3.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—